Strzalka-Mrozik, B.; Paprzycka, O.; Gruszka, O.; Madej, M.; Kruszniewska-Rajs, C.; Gola, J.M.; Turek, A.
Ranibizumab Modifies the Expression of Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Mononuclear Cells in Patients with Exudative Age-Related Macular Degeneration. J. Clin. Med. 2024, 13, 295.
https://doi.org/10.3390/jcm13010295
AMA Style
Strzalka-Mrozik B, Paprzycka O, Gruszka O, Madej M, Kruszniewska-Rajs C, Gola JM, Turek A.
Ranibizumab Modifies the Expression of Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Mononuclear Cells in Patients with Exudative Age-Related Macular Degeneration. Journal of Clinical Medicine. 2024; 13(1):295.
https://doi.org/10.3390/jcm13010295
Chicago/Turabian Style
Strzalka-Mrozik, Barbara, Olga Paprzycka, Oliwia Gruszka, Marcel Madej, Celina Kruszniewska-Rajs, Joanna Magdalena Gola, and Artur Turek.
2024. "Ranibizumab Modifies the Expression of Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Mononuclear Cells in Patients with Exudative Age-Related Macular Degeneration" Journal of Clinical Medicine 13, no. 1: 295.
https://doi.org/10.3390/jcm13010295
APA Style
Strzalka-Mrozik, B., Paprzycka, O., Gruszka, O., Madej, M., Kruszniewska-Rajs, C., Gola, J. M., & Turek, A.
(2024). Ranibizumab Modifies the Expression of Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Mononuclear Cells in Patients with Exudative Age-Related Macular Degeneration. Journal of Clinical Medicine, 13(1), 295.
https://doi.org/10.3390/jcm13010295